Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

Video content above is prompted by the following:

• What labs do you routinely monitor for CRS and ICANs – and how frequently?
• What type of prophylaxis and/or safety management are you applying to address CRS and ICANs?
• Does your institution have a standard operating procedure or guideline?
  • What percentage of your patients have required either steroids, tocilizumab, and/or anakinra for CAR-related toxicities?
• What are some other pertinent acute and long-term toxicities of CAR T-cell therapy to monitor for?
• Do you utilize antimicrobial prophylaxis, growth factor agents and IV immunoglobulin in your practice?
• When weighing treatment options, how heavily is CAR-T AE profile considered?
  • Does the safety profile of obe-cel change your perspective of using CAR-T? If so, how may it potentially affect your decision making?